Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immutep Ltd ( (AU:IMM) ) just unveiled an update.
Immutep Limited announced promising results from its Phase IIb trial of eftilagimod alfa (efti) in combination with KEYTRUDA® for head and neck cancer patients with PD-L1 CPS <1. The trial demonstrated a median overall survival of 17.6 months, significantly surpassing current standard treatments. This combination therapy addresses a high unmet need for patients with no available chemotherapy-free options, showing potential for regulatory approval discussions with the FDA. The safety profile remains favorable, and the company plans to continue data analysis and regulatory discussions.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in the field of Lymphocyte Activation Gene-3 (LAG-3) therapeutics, aiming to stimulate or suppress the immune response. Immutep’s product portfolio includes treatments for various solid tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer.
YTD Price Performance: -10.31%
Average Trading Volume: 5,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: $254.2M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.